Earlier menopause is associated with both reduced cognitive performance and gray matter volume: a population-based cross-sectional study
========================================================================================================================================
* Nitsan Schwarz
* Daniel Harlev
* Eyal Bergmann
* Noham Wolpe
## Abstract
**Background** Age at menopause varies widely across women, yet little is known about how this relates to long-term behavioral and brain-structural changes. Previous research has focused primarily on the menopausal transition itself, and the few studies investigating cognitive outcomes suggest reduced age-related cognitive performance with earlier menopause.
**Objectives** This study aims to investigate whether earlier menopause onset is associated with reduced cognitive performance and brain structure in later-life, in the same cohort of postmenopausal women.
**Methods** We analyzed data from the Cambridge Centre of Neuroscience and Aging, which included 747 postmenopausal women who underwent cognitive testing (Addenbrooke’s Cognitive Examination Revised, ACE-R). A subset (n=188) was additionally tested with a fluid intelligence test and underwent structural brain scans to measure gray and white matter volume (GMV and WMV). Multiple linear regression models were used to evaluate the association between menopause age and cognitive performance, as well as grey matter volume, controlling for chronological age.
**Results** Earlier menopause onset was associated with lower cognitive performance, as measured by the ACE-R (*t*(719)=2.81, *p*=0.005). Similar results were found for fluid intelligence (*t*(146) = 3.116, *p*=0.002). Structural brain analyses showed that a reduction of one year at the age of menopause onset was associated with a reduction of 2370mm3 in total grey matter volume (*t*(182)=3.37, *p*=0.001). No significant interactions were observed between menopause onset age and chronological age for any of the outcomes. GMV was a partial mediator between age at menopause onset and cognitive performance, while controlling for age.
**Conclusion** Women with earlier menopause show both reduced cognitive performance and lower GMV, suggesting that GMV reduction may be one mechanism linking earlier menopause to cognitive decline. However, the cross-sectional nature of this study prevents causal conclusions, and longitudinal research is needed to establish causal links and to explore potential targeted interventions.
## Introduction
Menopause timing is increasingly recognized as an important factor influencing long-term brain health, but its effects on aging-related cognitive and structural brain changes remain poorly understood. With increasing life expectancy, understanding the role of menopause timing in cognitive and brain aging, as well as its contribution to sex-specific differences in brain health, is essential for targeted interventions.
The menopausal transition is defined as the permanent cessation of ovulation and hence menstruation due to ovarian failure, and is influenced by numerous factors such as nutrition, exercise, number of pregnancies and childbirths, diet, and socioeconomic background1–3. This transition ends in the postmenopausal stage, defined by 12 consecutive months without menstruation after which a woman’s ovaries do not release eggs and produce minimal estrogen2,4. In postmenopausal women, symptoms such as disturbed sleep, weight gain, and increased risks for osteoporosis and cardiovascular disease are common5. Cognitive health is also adversely affected, with studies linking menopause to age-related cognitive decline2,6. Moreover, recent studies suggest a relationship between menopause and accelerated brain aging, as evidenced by volumetric differences between postmenopausal and pre- or peri-menopausal women7,8.
Although general postmenopausal symptoms are widely known, less is understood about how the age at menopause onset affects these processes. Menopause generally occurs around age 51, with a typical range between 45 and 55 years1,9. However, approximately 10% of women experience early menopause (before age 45) and 1% of women experience premature ovarian insufficiency, where menopause occurs before the age of 4010,11. For women experiencing earlier menopause onset, particularly before the age of 45, the post-menopausal years come with increased risks compared to women with later menopause onset. These include a higher risk for cardiovascular disease, osteoporosis, and accelerated cognitive decline4,5,12.
Despite these findings, research on the relationship between menopausal timing and brain health remains limited in both quantity and quality. Existing research has explored the relationship between earlier menopause and cognitive performance, and earlier menopause and brain structure13,14. However, no study to date has evaluated both within the same cohort, limiting the ability to triangulate early menopause, reduced cognitive performance, and reduced brain structure in later life.
Our research aims to bridge this gap by examining how the timing of menopause onset relates to both long-term cognitive performance and brain structure. We hypothesized that an earlier onset of menopause would be associated with both reduced performance in gross cognitive performance and reduced GMV within the same cohort of women.
## Methods
### Participants
Data was obtained from the Cambridge Centre of Neuroscience and Aging, a large-scale research project launched in 2010 to investigate how individuals can best retain cognitive abilities into old age15. Participants were recruited from the general population within the Cambridge City area, UK, aiming to be representative of the UK population. All participants gave written informed consent prior to beginning the study. The study was approved by the Cambridgeshire 2 (now East of England - Cambridge Central) Research Ethics Committee, in accordance with the Declaration of Helsinki.
The project data was separated into stages, and the relevant stages for this study included: Stage 1, where 2591 adults aged 18-90 completed a home interview that included lifestyle questions and cognitive tests; and Stage 2, where approximately 700 participants underwent neuroimaging and additional cognitive testing15.
Out of the 2591 participants interviewed in Stage 1, 747 of the 1459 women reported being post-menopausal and were included in the analyses. Menopause onset was determined using the question, “How old were you when your periods stopped?”15.
### Behavioral measures
During Stage 1, participants were interviewed in their home to acquire demographic information and measures of cognitive, mental and physical health. Cognitive assessment included Addenbrooke’s Cognitive Evaluation – Revised (ACE-R), which is a validated and widely used cognitive battery that assesses gross cognitive performance for dementia screening across five cognitive domains: Memory, Orientation/Attention, Fluency, Language, and Visuospatial ability16. Overall, 747 postmenopausal women completed the ACE-R.
A subset of participants from Stage 1 continued to Stage 2, based on additional exclusion criteria. Exclusion criteria for Stage 2 were described extensively in the original report15, including cognitive impairment (Mini-Mental State Examination scores below 25), difficulty in communication, substance abuse, mobility issues, significant medical issues, and MRI contraindications. In this stage, the relevant assessments included a fluid intelligence test and structural imaging. For fluid intelligence, The Cattell Culture Fair, Scale 2 Form A (Cattell) was used, which evaluates critical cognitive processes like fluid reasoning which decline with age15,17,18. The Cattell test is made up of four timed subtests with individual nonverbal “puzzles”, including Series Completion (3 minutes), Classification (4 minutes), Matrices (3 minutes), and Conditions (2.5 minutes). Participants mark the answers to each subtest using pen-and-paper in a multiple-choice format, for a maximum score of 46 (1 point for each correct question)15. A composite score was computed as the first principal component from the Principal Component Analysis (PCA) to the four subtest scores. 17. In total, 155 postmenopausal women had a complete Cattell dataset.
#### Structural MRI
A 3T Siemens TIM Trio was used to assess white matter volume (WMV) and gray matter volume (GMV). Structural MRI data was acquired and preprocessed as described previously18. In short, T1-weighted image (MPRAGE, repetition time 2250 ms, echo time 2.99 ms, inversion time 900 ms, flip angle 9°, field-of-view 256 mm × 240 mm × 192 mm, isotropic 1 mm voxels) was acquired for each participant. Structural images were preprocessed using the automatic analysis batching system ([http://imaging.mrc-cbu.cam.ac.uk/imaging/AA](http://imaging.mrc-cbu.cam.ac.uk/imaging/AA)) in SPM1218. The images were segmented into gray and white matter using SPM12’s tissue priors, and we used total gray matter volume (GMV) and white matter volume (WMV) for the analyses. Total intracranial volume (TIV) was computed from the segmentation to account for differences in head size. In total, 188 postmenopausal women had valid structural MRI data.
#### Statistical Analyses
To investigate the relationship between menopause onset and ACE-R score, a multiple linear regression model was used with age at menopause onset and chronological age, as well as their interaction as predictors. Each individual subdomain of the ACE-R was also examined in an exploratory analysis. Women who reported their last menstrual period at below 25 years of age (n=0) or above 60 years of age (n=9) were excluded due to a suspected incorrect response, as done previously19. Outliers in cognitive tests and GMV/WMV were defined as +/-3 standard deviations from the mean and were excluded from analysis.
Three multiple linear regression models were conducted with Cattell test scores, GMV, and WMV as the dependent variables. GMV and WMV were adjusted to TIV to account for differences in head size. The independent variables were menopause onset age, chronological age, and their interaction. MRIcron software was used for visualization of GMV and WMV ([http://www.nitrc.org/projects/mricron](http://www.nitrc.org/projects/mricron)).
A bootstrapped mediation analysis was conducted using multiple regression models to examine the effect of GMV on the relationship between menopause onset and cognitive performance. The mediation model was estimated with 5000 bootstrap resamples to obtain bias-corrected confidence intervals. All variables were Z-scored prior to the analysis. Chronological age was included as a covariate for all regression models.
All analyses were completed using Python version 3.10.020.
## Results
We first evaluated our study sample in comparison to the global prevalence of menopause onset. The sample included 2.9% of women who would be classified as experiencing premature ovarian insufficiency and 7.9% who would be classified as early menopause, which is consistent with global prevalence estimates22. Participant demographics can be seen in Table 1.
View this table:
[Table 1.](http://medrxiv.org/content/early/2025/02/24/2025.02.22.25322720/T1)
Table 1. Demographic data of Cam-CAN cohorts for each evaluation; ACE-R, Cattell and neuroimaging.
Groups are split up into early and premature menopause onset (<45), normal menopause onset (45-55), and late menopause onset (>55) for organization purposes only. The rest of the data focuses on continuous menopause onset.
### Study Sample
*Participant demographics are summarized in Table 1*.
### Cognitive Performance
We first conducted a multiple linear regression to test for the association between age at menopause onset, current age and their interaction on ACE-R score (Table 2). The model was significant at (*R*2 = 0.22, *F*(2, 719) = 102.5, *p* < 0.001). There was no significant interaction between age at menopause onset and current age in predicting ACE-R (*t*(719) =-0.81, *p =* 0.42). Importantly, however, there was a significant association between age at menopause onset and ACE-R score (*t*(719) = 2.81, *p =* 0.005), indicating that earlier menopause onset was associated with lower cognitive performance, independently from current age. Specifically, a reduction of one year in the age of menopause onset corresponded to a 0.15-point decrease in ACE-R score (Fig. 1). The association remained significant, although weaker, when including education in the model.
View this table:
[Table 2.](http://medrxiv.org/content/early/2025/02/24/2025.02.22.25322720/T2)
Table 2. Results of the multiple linear regression analysis, examining the effect of age at menopause onset, current age, and their interaction on ACE-R score.
Model 1 included the intercept, menopause onset and age; model 2 included the interaction term Onset*Age. All predictors are reported using Model 1, except for the interaction term (Model 2).
[Figure 1.](http://medrxiv.org/content/early/2025/02/24/2025.02.22.25322720/F1)
Figure 1.
Generalized linear model demonstrating relationship between menopause onset age and ACE-R score, with chronological age shown.
Exploratory, domain-specific analyses showed that Language and Visuospatial domains followed the same trend as overall ACE-R score (Supplementary Material). Similar results were also found for the Cattell (Supplementary Material).
### Structural imaging
After showing an association between two independent cognitive tests and age at menopause onset, we investigated the relationship between brain structure and age at menopause onset. We conducted a linear regression analysis on GMV and WMV, adjusted to total intracranial volume, to see if this trend could also be seen in brain structure. The model for GMV was significant (*R**2*=0.22, *F*(2, 182)= 24.53, *p* < 0.001). To account for individual differences in head size, we analyzed GMV as the ratio between GMV and total intracranial volume (TIV), as typically done (Table 3). The results suggest that that earlier menopause onset was significantly associated with lower GMV independently of age. Specifically, a reduction of one year in the age of menopause onset corresponded to a 0.0014 decrease in the GMV to TIV ratio, or 2370mm3 in total GMV (Fig. 2). The model with white matter volume (WMV) as the dependent variable showed no significant association with age at menopause onset (*t*(182) =-0.20, *p =* 0.84)
View this table:
[Table 3.](http://medrxiv.org/content/early/2025/02/24/2025.02.22.25322720/T3)
Table 3. Results of the multiple linear regression analysis, examining the effect of age at menopause onset, chronological age, and their interaction on GMV (as GMV to TIV ratio to account for TIV).
Model 1 included the intercept, menopause onset and age; model 2 included the interaction term Onset*Age. All predictors are reported using Model 1, except for the interaction term (Model 2).
[Figure 2.](http://medrxiv.org/content/early/2025/02/24/2025.02.22.25322720/F2)
Figure 2.
A) Horizontal sections of white matter (left) and gray matter (right), as computed during segmentation. B) Generalized linear model demonstrating relationship between menopause onset age and gray matter volume (GMV), colored by age.
[Figure 3.](http://medrxiv.org/content/early/2025/02/24/2025.02.22.25322720/F3)
Figure 3.
Mediation model of menopause onset, GMV, and cognitive performance (ACE-R Score). A mediation model illustrating the relationships between menopause onset, GMV, and ACE-R Score. The numbers next to the arrows represent standardized path coefficients. Solid arrows indicate statistically significant paths (*p < 0.05, **p < 0.01, \***|p < 0.001). The indirect effect (c - c’) and its confidence interval are reported at the top.
We conducted an exploratory mediation analysis to examine whether GMV statistically mediates the relationship between menopause onset and cognitive performance (ACE-R score), while accounting for age. In the GLM, menopause onset significantly predicted GMV (path *a* = 0.001, *p 3*= 0.004), and GMV significantly predicted ACE-R (path *b* = 4.546, *p* = 0.003). The total effect of menopause onset on ACE-R was significant (*c* = 0.031, *p* < 0.001). The indirect effect (*c* - *c*’ = 0.005, 95% CI [0.0008, 0.011]) was significant (*p* = 0.006). The direct effect remained significant after accounting for GMV (*c*’ = 0.026, *p* < 0.001), suggesting that GMV explains part of the association between menopause onset and cognitive performance.
## Discussion
While the few studies in the field have looked at cognition and neuroimaging separately, our study is unique in that it evaluated both cognition and brain structure in the same cohort of postmenopausal women. Our findings demonstrate a significant relationship between age at menopause onset and both reduced cognition and GMV, independently of current age. The mediation analysis, which is more limited in a cross-sectional context, suggests that women with earlier menopause show both reduced cognitive performance and grey matter volume.
Both the ACE-R and fluid intelligent assessments showed a significant negative association with earlier menopause onset. These results are consistent with previous studies showing associations between cognitive decline and women experiencing premature, early and earlier-onset menopause2,23,24. Moreover, our findings add to this line of research by linking earlier menopause to fluid intelligence performance, which is highly sensitive to aging17. These findings suggest that women who experience earlier menopause may exhibit signs of accelerated cognitive aging, with lower cognitive performance later in life. However, the lack of a significant interaction between menopause age and chronological age indicates that while earlier menopause is linked to lower cognitive function, it does not appear to alter the rate of age-related cognitive decline. Longitudinal research in the field can specifically test these hypotheses.
Interestingly, exploratory analyses on the subdomains of the ACE-R suggested that a specific reduction in Language, Visuospatial and Orientation/Attention domains were most strongly associated with age at menopause onset. Research has suggested that language and visuospatial abilities in old age are specifically predictive of vascular dementia risk 25. Our findings that earlier menopause onset is associated with a reduction in the scores of the ACE-R subdomains that are associated with vascular dementia reflect an urgent need for further sex-specific research in dementia mechanisms; especially as estrogen exposure, which is known to drop dramatically during and post-menopause, has been linked specifically to vascular dementia risk26.
In terms of differences in brain structure, earlier menopause onset was significantly associated with reduced GMV, independently of age, suggesting that menopause timing has a measurable and lasting impact on brain structure. Differences in GMV statistically mediated the relationship between age at menopause onset and cognitive performance, indicating that GMV may play a role in linking early menopause to cognitive decline. While lower GMV may be one mechanism linking early menopause to reduced cognitive performance, this hypothesis requires confirmation through longitudinal research. Future studies should investigate the temporal dynamics between menopause timing, brain structure changes, and cognitive decline, as well as explore potential interventions to mitigate these effects.
GMV loss is known to be associated with increased risk of dementia, which suggests that earlier menopause could predispose women to structural brain changes that contribute to dementia risk later in life and possibly vascular dementia in particular27. Notably, there was no association between menopause onset and white matter volume, further suggesting that menopause influence on brain structure is specific to changes in GMV. However, future research should also use complementary techniques, such as diffusion weighted imaging.
Mechanistically, these findings align with both human and animal research theories that estrogen is neuroprotective26. Estrogen, known for its neuroprotective properties, supports synaptic plasticity and neuronal health, and its abrupt decline during menopause is hypothesized to play a key role in accelerated brain aging2,3,13. Recent theories propose that earlier menopause could lead to a longer duration of low estrogen exposure after midlife, possibly contributing to decline of cognition and GMV26. While it is important to note that our study did not measure levels of ovarian hormones in our cohort, the knowledge of estrogen decline post-menopause and sex-specific disproportion in dementia demands more research into how ovarian hormones play a part in dementia prediction. Hormone replacement therapy (HRT), specifically, is known to reduce the risk of cognitive decline when initiated during the menopausal transition, and potentially mitigate the negative effects of estrogen depletion2,26. However, the timing of HRT is critical, as seen by the “critical window” hypothesis which suggests that HRT is neuroprotective only when administered within five years of menopause28,29, and that administration of HRT in older post-menopausal women could even be detrimental to cognitive health30,31.
### Strengths and Limitations
A key strength of this study is the integration of cognitive and fluid intelligence assessments, as well as neuroimaging, within the same cohort. Existing research focuses separately on either cognitive assessments or neuroimaging, and so this integration allows us to draw connections between these critical domains. By combining both approaches, our study describes a more comprehensive understanding of how menopause timing influences long-term brain health. Research on menopause onset and long-term brain health is still emerging, with the first study linking GMV to menopause onset published in 202414. Given the inconclusive findings on early menopause, cognition, and neuroimaging, our results urge a greater look at menopause onset studies relating to cognition and neuroimaging, and as a mediator of GMV.
In terms of limitations, we did not collect data on HRT use. The lack of HRT data prevents us from distinguishing between natural age-related changes and those potentially attenuated by hormonal intervention. Future research should explicitly account for HRT use to understand its timing effects on both cognition and GMV. Another limitation is the exclusion of participants with low cognitive performance from the fluid intelligence and neuroimaging analyses. This exclusion criterion may have inadvertently biased our sample by removing those most vulnerable to cognitive decline, therefore limiting the generalizability of our findings to the broader population of postmenopausal women. It is important to note that this was a cross-sectional design using a self-report of menopause onset.
## Conclusions
Our findings reveal significant associations between earlier menopause onset and both reduced cognitive performance and GMV, independently of age, in the same cohort of postmenopausal women. The results suggest that GMV reduction may be one mechanism linking earlier menopause to cognitive decline. Longitudinal studies are highly needed to establish causal links and to explore potential targeted interventions to mitigate the possible detrimental effects of earlier menopause.
## Data Availability
All data produced in the present study are available upon reasonable request to the authors.
## Supplementary Materials
### ACE-R Subdomains
Domain-specific analyses showed that Language and Visuospatial domains, linked to vascular dementia in literature 25, followed the same trend as overall ACE_R score, with Language (*t*(719)= 2.64, *p*=0.005), Visuospatial (*t* (719)= 2.06, *p*=0.040), and Orientation/Attention (*t*(719)= 2.14, *p*=0.033) domains significantly associated with menopause onset. The other domains (Fluency and Memory) showed no significant relationship with menopause onset age (Table 4). This is visualized in Fig. 4.
View this table:
[Table 4:](http://medrxiv.org/content/early/2025/02/24/2025.02.22.25322720/T4)
Table 4: Multiple linear regression association between ACE-R domains and menopause onset age (Onset), with chronological age as a covariate.
Results significant to menopause onset are highlighted.
View this table:
[Table 5.](http://medrxiv.org/content/early/2025/02/24/2025.02.22.25322720/T5)
Table 5. Results of the multiple linear regression analysis, examining the effect of age at menopause onset, current age, and their interaction on Cattell score.
Model 1 included the intercept, menopause onset and age; model 2 included the interaction term Onset*Age. All predictors are reported using Model 1, except for the interaction term (Model 2).
[Figure 4.](http://medrxiv.org/content/early/2025/02/24/2025.02.22.25322720/F4)
Figure 4. GLM Plots for ACE-R Subdomains.
The plots illustrate generalized linear model relationships between menopause onset age and performance in five cognitive domains of the ACE-R: Language (A), Memory (B), Orientation/Attention (C), Fluency (D) and Visuospatial (E) with chronological age visualized by color.
### Fluid Intelligence: Cattell Test
In a subset of participants who completed Stage 2, we investigated whether a relationship with age at menopause onset would be found for performance in the Cattell test, such as that found for ACE-R. The model was significant (*R*2= 0.35, *F(2, 146)*= 38.45, *p*<0.001), and there was a small but significant association between age at menopause onset and Cattell score, above and beyond current age (*t*(146) = 3.116, *p*=0.002) (Table 3). Specifically, a reduction of one year in the age of menopause onset corresponded to a 0.15-point decrease in the Cattell score (Fig. 5).
[Figure 5.](http://medrxiv.org/content/early/2025/02/24/2025.02.22.25322720/F5)
Figure 5.
Generalized linear model demonstrating relationship between menopause onset age and ACE-R score, with chronological age shown.
* Received February 22, 2025.
* Revision received February 22, 2025.
* Accepted February 24, 2025.
* © 2025, Posted by Cold Spring Harbor Laboratory
The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.
## References
1. 1.Laven JSE. Early menopause results from instead of causes premature general ageing. Reprod Biomed Online. 2022 Sep 1;45(3):421–4.
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=35523711&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
2. 2.Sochocka M, Karska J, Pszczołowska M, Ochnik M, Fułek M, Fułek K, et al. Cognitive Decline in Early and Premature Menopause. Int J Mol Sci. 2023 Jan;24(7):6566.
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=37047549&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
3. 3.Cavalcante MB, Sampaio OGM, Câmara FEA, Schneider A, de Ávila BM, Prosczek J, et al. Ovarian aging in humans: potential strategies for extending reproductive lifespan. GeroScience. 2023 Aug;45(4):2121–33.
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=36913129&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
4. 4.Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric. 2015 Jul 4;18(4):483–91.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3109/13697137.2015.1020484&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=25845383&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
5. 5.Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: Long-term health consequences. Maturitas. 2010 Feb 1;65(2):161–6.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.maturitas.2009.08.003&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=19733988&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
[Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000274944600013&link_type=ISI)
6. 6.Henderson VW, St. John JA, Hodis HN, McCleary CA, Stanczyk FZ, Karim R, et al. Cognition, mood, and physiological concentrations of sex hormones in the early and late postmenopause. Proc Natl Acad Sci. 2013 Dec 10;110(50):20290–5.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMjoiMTEwLzUwLzIwMjkwIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjUvMDIvMjQvMjAyNS4wMi4yMi4yNTMyMjcyMC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=)
7. 7.Kim GW, Park K, Jeong GW. Effects of Sex Hormones and Age on Brain Volume in Post-Menopausal Women. J Sex Med. 2018 May;15(5):662–70.
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=29628218&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
8. 8.Kim TH, Kim B, Kim YR, Jeong CW, Lee YH. Gray matter differences associated with menopausal hormone therapy in menopausal women: a DARTEL-based VBM study. Sci Rep. 2023 Jan 25;13(1):1401.
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=36697505&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
9. 9.Verdonk P, Bendien E, Appelman Y. Menopause and work: A narrative literature review about menopause, work and health. Work Read Mass. 72(2):483–96.
10. 10.Talaulikar V. Menopause transition: Physiology and symptoms. Best Pract Res Clin Obstet Gynaecol. 2022 May 1;81:3–7.
11. 11.Santoro N, Roeca C, Peters BA, Neal-Perry G. The Menopause Transition: Signs, Symptoms, and Management Options. J Clin Endocrinol Metab. 2021 Jan 1;106(1):1–15.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1210/clinem/dgaa764&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=33095879&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
12. 12.Stefanowski B, Kucharski M, Szeliga A, Snopek M, Kostrzak A, Smolarczyk R, et al. Cognitive decline and dementia in women after menopause: Prevention strategies. Maturitas. 2023 Feb 1;168:53–61.
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=36493633&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
13. 13.Boyle CP, Raji CA, Erickson KI, Lopez OL, Becker JT, Gach HM, et al. Estrogen, brain structure, and cognition in postmenopausal women. Hum Brain Mapp. 2021;42(1):24–35.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/hbm.25200&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=32910516&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
14. 14.Mensegere A, Singh S, Stezin A, Sundarakumar JS, Issac TG. Effect of early menopause on cognition and brain morphology in an Urban Indian Cohort. Alzheimers Dement J Alzheimers Assoc. 2024 Aug;20(8):5607–16.
15. 15.Shafto MA, Tyler LK, Dixon M, Taylor JR, Rowe JB, Cusack R, et al. The Cambridge Centre for Ageing and Neuroscience (Cam-CAN) study protocol: a cross-sectional, lifespan, multidisciplinary examination of healthy cognitive ageing. BMC Neurol. 2014 Oct 14;14:204.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12883-014-0204-1&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=25412575&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
16. 16.Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. 2006 Nov;21(11):1078–85.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/gps.1610&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=16977673&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
[Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000242253400011&link_type=ISI)
17. 17.Kievit RA, Davis SW, Mitchell DJ, Taylor JR, Duncan J, Henson RNA. Distinct aspects of frontal lobe structure mediate age-related differences in fluid intelligence and multitasking. Nat Commun. 2014 Dec 18;5(1):5658.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/ncomms6658&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=25519467&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
18. 18.Taylor JR, Williams N, Cusack R, Auer T, Shafto MA, Dixon M, et al. The Cambridge Centre for Ageing and Neuroscience (Cam-CAN) data repository: Structural and functional MRI, MEG, and cognitive data from a cross-sectional adult lifespan sample. NeuroImage. 2017 Jan;144(Pt B):262–9.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.neuroimage.2015.09.018&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=26375206&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
19. 19.Pokoradi AJ, Iversen L, Hannaford PC. Factors associated with age of onset and type of menopause in a cohort of UK women. Am J Obstet Gynecol. 2011 Jul 1;205(1):34.e1-34.e13.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ajog.2011.06.078&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=21514918&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
20. 20.Van Rossum G, Drake FL. Python 3 Reference Manual. Scotts Valley, CA: CreateSpace; 2009. 242 p.
21. 22.Giri R, Vincent AJ. Prevalence and Risk Factors of Premature Ovarian Insufficiency/Early Menopause. Semin Reprod Med. 2020 Sep;38(04/05):237–46.
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=33434933&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
22. 23.Schelbaum E, Loughlin L, Jett S, Zhang C, Jang G, Malviya N, et al. Association of Reproductive History With Brain MRI Biomarkers of Dementia Risk in Midlife. Neurology. 2021;97:2328–39.
23. 24.Kuh D, Cooper R, Moore A, Richards M, Hardy R. Age at menopause and lifetime cognition. Neurology. 2018 May 8;90(19):e1673–81.
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=29643079&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
24. 25.Potts C, Richardson J, Bond RB, Price RK, Mulvenna MD, Zvolsky P, et al. Reliability of Addenbrooke’s Cognitive Examination III in differentiating between dementia, mild cognitive impairment and older adults who have not reported cognitive problems. Eur J Ageing. 2022 Sep;19(3):495–507.
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=34566550&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
25. 26.Nguyen DH, Cunningham JT, Sumien N. Estrogen receptor involvement in vascular cognitive impairment and vascular dementia pathogenesis and treatment. GeroScience. 2021 Feb 1;43(1):159–66.
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=32902819&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
26. 27.Nakazawa T, Ohara T, Hirabayashi N, Furuta Y, Hata J, Shibata M, et al. Multiple-region grey matter atrophy as a predictor for the development of dementia in a community: the Hisayama Study. J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):263–71.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiam5ucCI7czo1OiJyZXNpZCI7czo4OiI5My8zLzI2MyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDI1LzAyLzI0LzIwMjUuMDIuMjIuMjUzMjI3MjAuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)
27. 28.Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, et al. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study. PLOS Med. 2015 Jun 2;12(6):e1001833.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pmed.1001833&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=26035291&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
28. 29.Maki PM. Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause N Y N. 2013 Jun;20(6):695–709.
29. 30.Greendale GA, Huang MH, Wight RG, Seeman T, Luetters C, Avis NE, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009 May 26;72(21):1850–7.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1212/WNL.0b013e3181a71193&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=19470968&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F24%2F2025.02.22.25322720.atom)
30. 31.McCarrey AC, Resnick SM. Postmenopausal hormone therapy and cognition. Horm Behav. 2015 Aug;74:167–72.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.yhbeh.2015.04.018&link_type=DOI)